Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
NCT07325630
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
IBI363 + Chemotherapy
Interventions
DRUG:
IBI363 + chemotherapy
Sponsor
Zhejiang Cancer Hospital